Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASC30_39FDC
- Development stage
- Preclinical
- Lead developer
- Ascletis Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ASC30_39FDC is an investigational small molecule fixed-dose combination (FDC) therapy being developed by Ascletis Pharma for the treatment of obesity. The combination targets two key metabolic pathways: the glucagon-like peptide-1 receptor (GLP-1R) and the amylin receptor (specifically via a Small-molecule Amylin Receptor Agonist, or SARA). By combining these two mechanisms into a single formulation, the therapy aims to achieve superior weight loss and metabolic benefits compared to monotherapy through synergistic appetite suppression and improved glucose regulation. As of 2024, the program is in the discovery phase.
02
Targets
AMY receptor (Calcitonin receptor (with ramps))GLP1R (GLP-1R)
Beyond the preview
Go deeper on ASC30_39FDC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASC30_39FDC.